Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$1.78
+17.1%
$1.49
$1.09
$7.66
$126.36M2.941.34 million shs879,804 shs
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$2.26
+3.9%
$1.57
$0.63
$2.75
$120.55M0.961.64 million shs867,965 shs
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$0.61
+4.5%
$0.53
$0.36
$4.06
$99.16M32.70 million shs1.07 million shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$7.39
+4.4%
$6.90
$5.35
$30.03
$27.20M-1.95165,931 shs45,518 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
+2.01%+6.29%-12.14%+26.14%-66.37%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
+12.20%+11.86%+25.43%+232.36%+63.16%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-4.53%-4.56%-7.97%+39.95%-80.02%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-0.91%+4.12%-14.18%+8.79%-73.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
1.4471 of 5 stars
3.31.00.00.00.61.70.6
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.4416 of 5 stars
3.25.00.00.00.62.50.0
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
3.4684 of 5 stars
3.52.00.00.02.24.21.3
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.6257 of 5 stars
3.32.00.00.01.90.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.50
Moderate Buy$12.00574.38% Upside
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.40
Hold$7.00210.42% Upside
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
3.00
Buy$6.25925.26% Upside
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
2.50
Moderate Buy$30.00305.95% Upside

Current Analyst Ratings Breakdown

Latest TPST, MIST, CCCC, and TNYA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$5.00
5/9/2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/25/2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/10/2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$16.00 ➝ $16.00
4/10/2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Outperform ➝ Sector Perform$7.00 ➝ $9.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$35.58M3.55N/AN/A$3.06 per share0.58
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1M120.55N/AN/A$0.25 per share9.02
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/A$1.07 per shareN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A$5.66 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$105.32M-$1.47N/AN/AN/A-259.60%-45.86%-28.96%7/30/2025 (Estimated)
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$41.52M-$0.78N/AN/AN/AN/A-329.85%-67.20%8/6/2025 (Estimated)
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$111.13M-$1.16N/AN/AN/AN/A-92.20%-74.53%8/14/2025 (Estimated)
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$41.84M-$17.98N/AN/AN/AN/A-305.51%-119.74%8/14/2025 (Estimated)

Latest TPST, MIST, CCCC, and TNYA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$0.19-$0.31-$0.12-$0.31N/AN/A
5/13/2025Q1 2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$3.71-$3.16+$0.55-$3.16N/AN/A
5/7/2025Q1 2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 million
5/7/2025Q1 2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$0.18-$0.24-$0.06-$0.24N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
N/AN/AN/AN/AN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
5.70
5.70
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
4.06
4.67
4.67
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/A
6.68
6.68
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
1.70
1.70

Institutional Ownership

CompanyInstitutional Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
86.18%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
90.54%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
15071.01 million64.81 millionOptionable
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
3053.46 million43.04 millionOptionable
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
110162.67 million83.53 millionOptionable
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
203.68 million3.51 millionOptionable

Recent News About These Companies

Tempest Therapeutics (NASDAQ:TPST) Trading Up 0.2% - Here's Why
TPST Tempest Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$1.78 +0.26 (+17.07%)
As of 12:17 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Milestone Pharmaceuticals stock logo

Milestone Pharmaceuticals NASDAQ:MIST

$2.26 +0.09 (+3.92%)
As of 12:11 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Tenaya Therapeutics stock logo

Tenaya Therapeutics NASDAQ:TNYA

$0.61 +0.03 (+4.51%)
As of 12:12 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$7.39 +0.31 (+4.38%)
As of 12:10 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.